Nektar’s Novel Eczema Drug Meets Trial Goals, But Differentiation From Dupixent Remains Unclear

Nektar Therapeutics’ biologic drug rezpegaldesleukin take a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses. The drug met the goals of a Phase 2b study, but analysts note that cross-trial measures show those results are short of the marks achieved by Dupixent, the top biologic…

Read More

How Smarter Metrics Can Unlock AI’s Potential in Healthcare

Healthcare doesn’t reward shortcuts. It rewards outcomes. AI will play a critical role in shaping those outcomes — but only if leaders measure what truly matters. The best AI implementations elevate expertise, improve quality and create space for innovation. The post How Smarter Metrics Can Unlock AI’s Potential in Healthcare appeared first on MedCity News.

Read More